Profound Medical Corp. (PROF): Price and Financial Metrics
GET POWR RATINGS... FREE!
PROF POWR Grades
- Growth is the dimension where PROF ranks best; there it ranks ahead of 74.64% of US stocks.
- PROF's strongest trending metric is Sentiment; it's been moving down over the last 130 days.
- PROF's current lowest rank is in the Value metric (where it is better than 6.51% of US stocks).
PROF Stock Summary
- PROF's price/sales ratio is 37.34; that's higher than the P/S ratio of 95.74% of US stocks.
- PROF's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 8.9% of US stocks.
- With a year-over-year growth in debt of 466.69%, PROFOUND MEDICAL CORP's debt growth rate surpasses 96.36% of about US stocks.
- Stocks that are quantitatively similar to PROF, based on their financial statements, market capitalization, and price volatility, are OVID, ASXC, MRIN, IPWR, and TTNP.
- Visit PROF's SEC page to see the company's official filings. To visit the company's web site, go to www.profoundmedical.com.
PROF Price Target
For more insight on analysts targets of PROF, see our PROF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.60 | Average Broker Recommendation | 1.3 (Strong Buy) |
PROF Stock Price Chart Interactive Chart >
PROF Price/Volume Stats
| Current price | $9.17 | 52-week high | $13.52 |
| Prev. close | $8.90 | 52-week low | $3.10 |
| Day low | $8.92 | Volume | 16,500 |
| Day high | $9.28 | Avg. volume | 34,326 |
| 50-day MA | $11.85 | Dividend yield | N/A |
| 200-day MA | $7.85 | Market Cap | 191.73M |
Profound Medical Corp. (PROF) Company Bio
Profound Medical Corp. operates as a medical device company. The Company develops and commercializes technology for the treatment of localized prostate cancer. Profound Medical offers its services worldwide.
Latest PROF News From Around the Web
Below are the latest news stories about PROFOUND MEDICAL CORP that investors may wish to consider to help them evaluate PROF as an investment opportunity.
Profound Medical Announces Fourth Quarter and Full Year 2022 Financial ResultsCompany confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSATORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2022. Unless specified otherwise, all amounts in this pres |
Profound Medical to Present at the 43rd Annual Cowen Health Care ConferenceTORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time. The presentation will be br |
Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to FollowTORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business deve |
Profound Medical to Present at the 2022 Jefferies London Healthcare ConferenceTORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:20 p.m. GMT. The presentation will be broadcast l |
Profound Medical Announces Third Quarter 2022 Financial ResultsTORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Rep |
PROF Price Returns
| 1-mo | -27.51% |
| 3-mo | N/A |
| 6-mo | 124.75% |
| 1-year | -3.78% |
| 3-year | -8.85% |
| 5-year | 20.03% |
| YTD | -15.79% |
| 2022 | -3.03% |
| 2021 | -45.38% |
| 2020 | 87.76% |
| 2019 | 160.71% |
| 2018 | -35.64% |
Loading social stream, please wait...